Is Thymosin Alpha-1 Legal in Wisconsin? How to Access It Legally
HealthRX.com
FDA gives thymosin alpha-1 no approval or recognized pathway
Key numbers
- 1.6 mgDose on the Italian Zadaxin label, which has no US-approved equivalentSource: fda.gov, as cited Nov 7, 2026
- 45.8%HBeAg loss at 72 weeks with interferon plus thymosin alpha-1 in one trial of 98 adultsSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 1,349 adultsAdults with chronic hepatitis B pooled across 10 trials in a 2026 Cochrane reviewSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
At a glance
- FDA approval / none; no US application for thymosin alpha-1 or thymalfasin [1]
- State-licensed pharmacy list / in none of the three categories, updated May 14, 2026 [2]
- Outsourcing facility list / category 3, 'nominated without adequate support', updated March 21, 2025 [3]
- FDA safety view / immunogenicity for certain routes, peptide purity and characterization, safety data inadequate [4]
- Advisory committee vote / 4 yes, 17 no, December 4, 2024 [5]
- Approved outside the US / Italy as an influenza-vaccine adjuvant, India for chronic hepatitis B, Hong Kong [1]
- US-approved dose / none [1]
Is thymosin alpha-1 FDA-approved?
No. A Drugs@FDA search found no US application for thymosin alpha-1 or thymalfasin [1]. It holds four US orphan drug designations, but orphan designation is a separate process from approval [1]. Zadaxin, the finished 1.6 mg injection sold outside the US, is not interchangeable with bulk thymosin alpha-1 powder [1].
What do FDA's compounding lists say?
State-licensed pharmacies compound against patient-specific prescriptions; outsourcing facilities may also distribute compounded drugs for office stock without a patient-specific prescription [6]. FDA keeps a separate bulk-substance list for each.
On the state-licensed pharmacy list, updated May 14, 2026, thymosin alpha-1 is in none of the three categories, so FDA's category 1 policy of generally taking no action against qualifying compounders does not apply to it [2][3]. On the outsourcing facility list, updated March 21, 2025, it is in category 3, 'nominated without adequate support' [3].
FDA's stated concerns remain posted: 'significant risk for immunogenicity for certain routes of administration', peptide-impurity and characterization problems, and safety information 'inadequate for the agency to sufficiently understand the extent of any safety issues' [4]. Thymosin alpha-1 now sits in the 'nominated but withdrawn' table on that page because the nominators withdrew it [4].
On December 4, 2024, FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no on both the free base and the acetate; members who voted no cited no compelling evidence of clinical effectiveness and safety [5]. Thymosin alpha-1 is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [7].
Where does that leave access?
There is no FDA-approved thymosin alpha-1 product in the US [1]. Compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness or quality before they reach patients [6].
Questions worth asking
What do the trials and the label show?
The Italian Zadaxin label gives 1.6 mg subcutaneously or intramuscularly twice weekly for 4 weeks from the first vaccination, repeated from week 8 to week 12, and contraindicates it in pregnancy and breastfeeding [1]. No US-approved dose exists [1].
A 2026 Cochrane review pooled 10 randomized trials in 1,349 adults with chronic hepatitis B and rated the effect on hepatitis B-related illness very uncertain; the reviewers said they were 'not sure' the drug helps [8]. In one double-blind trial of 98 adults, HBeAg loss at 72 weeks was 45.8% with interferon plus thymosin alpha-1 versus 28.0% with interferon plus placebo, a difference of 17.8% (95% CI -1.2 to 35.3, P=0.067) that was not statistically significant [9].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
Is thymosin alpha-1 legal in Wisconsin?
Do compounded drugs need a patient-specific prescription?
Is thymosin alpha-1 banned in sport?
Why did FDA's advisory committee vote against it?
References
Show all 10 referencesHide references
- U.S. Food and Drug Administration. Thymosin alpha-1 review, December 2024.
- U.S. Food and Drug Administration. Bulk drug substances list for state-licensed pharmacies and physicians.
- U.S. Food and Drug Administration. Bulk drug substances list for outsourcing facilities.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee, December 4, 2024.
- Human Drug Compounding Laws | FDA.
- U.S. Department of Health and Human Services. Peptide enforcement discretion policy, Appendix B. HHS peptide enforcement discretion policy
- Naing C, Ni H, Aung HH, Aye SN, Nikolova D, Poovorawan Y, et al. Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database Syst Rev. 2026.
- Lim SG, Wai CT, Lee YM, Dan YY, Sutedja DS, Wee A, et al. A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B. Antivir Ther. 2006.
- World Anti-Doping Agency. 2026 Prohibited List.